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Background. There is no universally accepted definition for hyperacusis, but in general it is characterised by decreased sound
tolerance to ordinary environmental sounds. Despite hyperacusis being prevalent and having significant clinical implications,much
remains unknown about current management strategies. Purpose. To establish the current position of research on hyperacusis and
identify research gaps to direct future research. Design and Sample. Using an established methodological framework, electronic
and manual searches of databases and journals identified 43 records that met our inclusion criteria. Incorporating content and
thematic analysis approaches, the definitions of hyperacusis, management strategies, and outcome measures were catalogued.
Results. Only 67% of the studies provided a definition of hyperacusis, such as “reduced tolerance” or “oversensitivity to sound.”
Assessments and outcomemeasures includedLoudnessDiscomfort Levels, theHyperacusisQuestionnaire, andTinnitusRetraining
Therapy (TRT) interview. Management strategies reported were Cognitive Behavioural Therapy, TRT, devices, pharmacological
therapy, and surgery. Conclusions. Management strategies were typically evaluated in patients reporting hyperacusis as a secondary
complaint or as part of a symptom set. As such the outcomes reported only provided an indication of their effectiveness
for hyperacusis. Randomised Controlled Trials are needed to evaluate the effectiveness of management strategies for patients
experiencing hyperacusis.
1. Introduction
Hyperacusis is the perception of everyday environmental
sound as being overwhelmingly loud or intense. Other
terminology in use includes reduced, decreased, or collapsed
sound tolerance. It differs from phonophobia which is an
episodic sound intolerance experienced by some people
during migraine attacks, sometimes associated with other
sensory sensitivities, and which abates as the attack recedes
[1]. It can also be differentiated from misophonia which is
an acquired aversive reaction to specific human generated
sounds such as eating sound or breathing, the response being
characterised by anger and sometimes rage [2, 3].
As with other subjective symptoms, data on the preva-
lence of hyperacusis is strongly influenced by how the enquiry
about the symptomwas worded. In children and adolescents,
the variability in wording of the enquiry in prevalence studies
has been found to be so great as to render comparison across
studies to be meaningless [4]. In a study of 7096 11-year-
old children in the UK, 3.7% answered affirmatively to the
question “do you ever experience oversensitivity or distress
to particular sounds?” [5]. In adults, variability of the ques-
tions asked across studies of hyperacusis also significantly
impacts on the ability to identify prevalence figures. Using
the question “Do you consider yourself sensitive to everyday
sounds?,” Andersson and colleagues [6] found that of 1,174
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adults that answered the question via either the Internet
or post, 8.6% (95% CI = 7.0–10.0) responded affirmatively.
Another Swedish study [7] in adults asked 3406 participants,
“Do you have a hard time tolerating everyday sounds that
you believe most other people can tolerate?” and found 9.2%
responded affirmatively, with 1.9% reporting that they had
been diagnosed with hyperacusis by a physician.
There is an apparent association between hyperacusis and
tinnitus, with 86% of adult patients with a primary complaint
of hyperacusis experience tinnitus [8] and 40% of patients
with a primary complaint of tinnitus experience hyperacusis
as well [9]. Many people with troublesome hyperacusis
have normal or age appropriate hearing thresholds, but
cochlear hearing loss has also been reported [10]. Medical
conditions associated with hyperacusis include closed head
injury, depression, posttraumatic stress syndrome, Williams
syndrome, and pain syndromes such as fibromyalgia [1]. The
physiological mechanisms that underpin hyperacusis are not
well understood, and there is no compelling animal model. A
consensus is emerging in the auditory neuroscience literature
that hyperacusis may be associated with a sustained and
persistent increase in central auditory gain [11].
A framework with which to categorise patients with
hyperacusis has been proposed [12]. The subtypes consisted
of hyperacusis that is characterised by loudness, annoyance,
fear, or pain. This schema was not based upon empirical data
and may serve to illustrate the various characteristics that
can define the lived experience of hyperacusis, rather than
to support diagnosis or treatment. Regardless, hyperacusis
is a complex symptom which can have negative effects
on daily functioning such as hearing, sleep, concentration,
and emotional well-being that can vary daily and between
individuals. Management, therefore, can be complex with
approaches taken including cognitive behaviour therapy,
Tinnitus Retraining Therapy, or sound therapy [13]. Com-
plex interventions such as these need to be developed and
evaluated in a systematic way to have confidence in the
effectiveness of the intervention for the given population [14].
The purpose of this scoping review is to identify research
gaps in existing literature and elements that should underpin
the design of any new studies. The aim of this scoping review
is to consider the current position of research on hyperacusis
in adults. Specifically, the objective here is to identify
(i) how hyperacusis is currently defined in research
studies,
(ii) How it is currently measured (i.e., what measures
are used for diagnosis and outcome and are they
adequate?),
(iii) What the level of evidence is for current management
options (i.e., what has been previously studied and to
what extent?).
2. Materials and Methods
This review is reported according to the methodological
framework developed by Arksey and O’Malley [15] using the
six-stage process. In this process (1) the purpose and research
questions were defined, (2) relevant studies were identified,
(3) studies were selected using an iterative approach through
title, abstract, and full-text screening by three members
of team (KF, IP, and GSS), (4) data were extracted and
charted by two members of the team (KF, IP), (5) the
results were collated, summarised, and reported, and (6) two
clinical experts, who were not involved in the data extraction
or collating and summarising results, were consulted and
reviewed the findings.
2.1. Eligibility Criteria. To be included, records were required
to report studies in which adults (≥18 years old) reported
hyperacusis as a primary complaint or secondary complaint
or as part of a symptom set. Records were included where
management strategies (i.e., interventions) were tested to
address hyperacusis. Records were eligible from Randomised
Controlled Trials (RCTs), nonrandomised control trials,
cohort studies, case series, and case studies. Review articles
including systematic reviews, epidemiology articles, and any
sources reporting personal/expert opinions were excluded.
No records were excluded based on controls used, outcomes
reached, timing, setting, or study design. Records were
excluded for studies reporting misophonia, phonophobia,
and loudness recruitment.
All included records were published in the English lan-
guage. Where multiple eligible unique records pertaining to
a single trial were identified, the record that was published
first was included and any secondary analyses of the datawere
excluded.
2.2. Search Strategy. The search strategy followed a rec-
ommended three-step approach [16, 17]. In Step 1, to test
keywords and search terms, a limited search in PsycINFO
and Embase was conducted, checking the availability of
relevant titles and abstracts.This allowed us to develop search
term combinations to use across a wider search in step
two. The search strategy included hyperacusis and terms for
identifying research studies, such as intervention, therapy,
treatment,management, assessment, outcome, and diagnoses
(diagnostic) with narrow terms such as measure and test
(Table 1). In Step 2, to identify relevant research studies,
electronic databases of peer reviewed journals were searched
in the Cochrane Ear, Nose and Throat Disorders Group
Trials Register; the Cochrane Central Register of Controlled
Trials (CENTRAL); PubMed; Embase; PsycINFO; Scopus;
Cumulative Index to Nursing and Allied Health Literature
(CINAHL); Web of Science; the International Standard
Randomised Controlled Trial Number (ISRCTN) registry;
ClinicalTrials.gov; the International Clinical Trials Registry
Platform (ICTRP); and Google Scholar. Specific search term
strategies were applied in each search engine, searching
article topics, titles, abstracts, and keywords. Where possible,
filters were applied to retrieve articles in the English language
and using human participants only. There was no restriction
in the search period as we wanted to include all available
research up until the present time.
In Step 3, to seek further eligible documents for inclusion,
we performed manual searches of the reference lists of any
relevant review articles which had hyperacusis in the title.
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Table 1: Search term strategies for hyperacusis interventions and outcome measures. CENTRAL = Cochrane Central Register of Controlled
Trials; CINAHL = Cumulative Index to Nursing and Allied Health Literature; ISRCTN = International Standard Randomised Controlled
Trial Number; ICTRP = the International Clinical Trials Registry Platform.
Search terms Search engine
Hyperacus∗ AND [assess∗ OR measure∗ OR test∗
OR outcom∗ OR Diagnos∗ OR defin∗ OR treat∗ OR
manag∗ OR therap∗ OR interv∗
Embase, PsycINFO, CENTRAL, Scopus, Web of Science
Hyperacus∗ AND [(assess∗ OR measure∗ OR test∗
OR diagnos∗ OR defin OR outcom∗ OR therap∗ OR
interv∗ OR treat∗ OR manag∗)]
Web of Science, Scopus, PubMed, CENTRAL, CINAHL Plus
Hyperacus∗ Cochrane ENT Disorders Group Trials Register
Hyperacusis ClinicalTrials.gov, ISRCTN, ICTRP
Hyperacusis AND [assessment OR measurement OR
test OR Outcome OR diagnosis OR definition OR
treatment ORTherapy OR intervention]
Google Scholar
In addition, manual searches of the most common journals
(determined using the interquartile rule for outliers) inwhich
eligible records had been sourced were conducted. The final
manual search was conducted in April 2017.
2.3. Study Selection. Articles identified through electronic
and manual searches were exported with citations, title, and
abstract into Endnote where duplicates were removed. Search
records were screened independently by two researchers out
of a team of three (KF, IP, andGSS), first screening by title and
abstract and then by full text. When disagreements regarding
the inclusion or exclusion of any given record arose, the
two researchers discussed their rationale until agreement was
reached or a third researcher (DH) was consulted to reach a
majority decision.
2.4. Data Extraction. A data extraction form was developed
and piloted on two included records and was subsequently
modified following team discussions. Data from each article
were extracted by two researchers (KF and IP). Data were
extracted on study characteristics, definition of hyperacusis,
assessment measures used, and interventions (Box 1).
3. Results
3.1. Study Selection. Figure 1 illustrates the flow of study
records identified, screened, included, and excluded (with
reasons for exclusion). Electronic searches yielded an initial
set of 1708 records. Duplicates were removed and of the
remaining 792 records, 710 were excluded because the title
and abstract indicated that the article did not fit our eligibility
criteria. Most commonly the studies excluded did not focus
on hyperacusis or did not report treatment of hyperacusis.
Manual searches of included records in review articles iden-
tified a further 27 potential articles which were subjected to
full-text screening. Manual searches in the selected journals
identified one additional eligible record. Sixty-seven records
were excluded at the full-text screening stage. Commonly,
this was because the record did not report on the treatment or
management of hyperacusis or was based on expert opinion
or a review of the literature. For 1 record the reference was
incomplete and could not be found. Full-text records could
not be located for a further 2 records. None of these records
could be traced, regardless of support from the University
of Nottingham librarian.The electronic and manual searches
created a final list of 43 eligible full-text records for data
collection.
3.2. Study Characteristics. Of the 43 included full-text arti-
cles, there were 34 journal articles, six conference papers, and
three book chapters. Articles were published from 1984, with
the majority published after 2001 and the most recent being
published in 2016. Records were predominantly reporting
studies from the USA, UK, Australia, India, South Korea,
and European countries. Of the included records, 23 were
case studies [19, 25–27, 34–38, 40–43, 49–58], seven were
cohort studies [28, 29, 39, 44, 46, 59, 60], five were RCTs
[18, 20, 21, 30, 47], four were Nonrandomised Controlled
Trials [22, 23, 31, 48], and four were retrospective studies
[24, 32, 33, 45].
3.3. Population Characteristics. Of the 43 included records,
16 studies [18, 19, 21–25, 38, 39, 41–43, 55–57, 60] included
patients reporting hyperacusis as a primary complaint. Of
these studies, nine (53%)were case studies and only two (12%)
were RCTs (Table 2). Equally, 16 studies [34–37, 40, 44, 45,
47, 49–54, 58, 59] included patients reporting hyperacusis
as part of a set of symptoms, the most common of which
were tinnitus, hearing loss, vertigo, or aural fullness. The
remaining 11 studies included patients reporting hyperacusis
as a secondary complaint to tinnitus [20, 26–28, 30–33, 48]
and/or hearing loss [29, 46]. Duration of the participants
hyperacusis was not reported in 29 studies [20–26, 28–33, 38,
39, 42–48, 50–53, 56, 57, 59]. For the remaining 14 studies
[18, 19, 27, 34–37, 40, 41, 49, 54, 55, 58, 60], the duration of
hyperacusis reported ranged from 6 weeks in a surgical case
study [55] to 27 years in an “acoustic training” case study [40].
3.4. Current Definitions for Hyperacusis. Fourteen studies
[26–28, 31–33, 44, 45, 47, 48, 51, 52, 54, 57] did not provide
a working definition of hyperacusis. Across the remaining
4 BioMed Research International
First author surname
Year of publication
Study Title
Publication type: journal article, report, conference paper, undergraduate dissertation, postgraduate dissertation,
book chapter, webpage, or other (please specify)
Country where study was conducted
Aim of study
Terminology used to describe hyperacusis
Study design: case report, case series, cohort study, retrospective study, non-randomised control trial, randomised
control trial, or other
Study design (if other)
Methods: questionnaire, focus groups, interviews, audiometric tests, clinical tests, medical/physical investigations,
or combination
Sample size for primary analysis (not follow up)
Study population: patients, general public, students or combination
Setting
Age
Gender
Hyperacusis complaint: primary, secondary or as part of symptom set
What are the comorbid conditions/syndrome/symptom set?
Hyperacusis-related symptoms reported
Average duration of hyperacusis in years (SD)
Measures used for screening of hyperacusis to the study
Assessment time points
Outcome measures used on patients with hyperacusis
Treatment primarily aimed at hyperacusis
Nature of therapeutic interventions reported (summarise key components)
Treatment outcomes from questionnaires
Treatment outcomes from LDLs
Treatment outcomes - anecdotal reports
Study limitations
Further research priorities specified
Box 1: Data extraction fields.
studies, common terminologies were used to define hyper-
acusis, with four main themes identified (Figure 2).
One theme that emerged from the definitions focused
on “reductions” in sound tolerance [24, 34, 38, 43, 50, 60].
Authors described hyperacusis as “a reduction of normal
tolerance for everyday sounds” [38], “decreased sound tol-
erance” [24], “lowered threshold for sound tolerance” [50],
or “the collapse of loudness tolerance” [43]. In contrast to
this, other studies emphasised the “increased sensitivity” to
sound [20, 29, 35, 39, 40, 42, 46, 53, 55]. This theme included
descriptors such as “hypersensitivity,” “oversensitivity,” or
“abnormal sensitivity” to define the degree of tolerance to
sounds (Figure 2). One author used descriptors that indicated
increased loudness, “a disproportionate growth in subjective
loudness of sounds” [49]. Other definitions referred to
“intolerance” to sounds that had been deemed as ordinary [18,
19, 21, 30, 37, 41, 58, 59]. Authors referred to “noise intolerance
to ordinary sounds” [58], “unusual intolerance” [18, 19], or
“intolerance to the loudness of sounds that most individuals
deem to be tolerable” [21].The last theme to emerge included
definitions that referred to the physical or emotional reaction
to the sound, such as “subject exhibits negative reactions”
[25], “abnormal, generally painful perception of loudness”
[23], or the “response or reaction from the auditory cortex”
[22, 36].
Underlying these themes, throughout, was the common
concept of the tolerance to sound being different from
“normal.” Definitions referred to sound tolerance of “normal
listeners” [38], “a normal person” [40], “a typical person” [19],
or “others” [43] in comparison to sound tolerance of patients
with hyperacusis. For example, Formby et al. [30] described
hyperacusis as a “general intolerance to the loudness of
sounds that would not typically be bothersome for most
individuals.” In some cases, the response to “ordinary” or
“everyday” environmental soundswas described as “unusual”
[18, 19, 55] or “abnormal” [22, 23, 36, 42], and in one case
the response was described as “exaggerated or inappropriate”
[19].
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Reasons
No focus on hyperacusis 8
No reported treatment of 
hyperacusis 25
Incomplete reference 1
Full text not accessible 2
Inappropriate type of study 4
Including age less than 18 years 11
Review/expert opinion 13
Duplicates 1
Ongoing trial 2
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information sources
n = 1708
Duplicates excluded
n = 1030
Titles assessed for eligibility
n = 1587
Abstracts assessed for eligibility
n = 1204
Full text assessed for eligibility
n = 110
Records included for data 
collection and synthesis
n = 43
n = 909
Records excluded
n = 383
Records excluded
n = 1094
n
Records excluded n = 67
Records identified through
manual searches
Figure 1: Flow chart of stages of study selection process.
Across the themes reductions, sensitivity, and intolerance,
some authors notedwithin theirworking definitions the overt
physical and emotional responses evoked by the perception of
sounds.These authors highlighted the “bothersome” [30, 39],
“distressing” [20], or “disabling” [37] nature of the sounds, the
“discomfort” [19, 40, 43, 49, 55] or “pain” [23, 49] caused by
the perception of sound, or the negative reaction to exposure
to sound [25]. In one case, Silverstein et al. [58] listed
associated symptoms of “emotional, social and physical”
reactions to hyperacusis within their working definition.
3.5. Assessment Tools Used for Diagnosis and Outcome. In
six studies (14%), the assessment tools used to quantify or
diagnosis hyperacusis were not stated [20, 21, 39, 43, 47, 59].
Sixteen studies used clinical interviews (history and examina-
tion) to assess patient symptoms [28, 29, 35, 36, 41, 42, 46, 49–
57]. Most of these studies were case series and reports, with
some implying that interviews were used but not explicitly
stating this.
Of the remaining 21 studies [18, 19, 22–27, 30–34, 37,
38, 40, 44, 45, 48, 58, 60], audiometric measures (Loud-
ness Discomfort Levels (LDLs), Maximum Comfort Lev-
els (MCLs), and Dynamic Range (DR)) and patient self-
reported measurement tools (Baltimore questionnaire (VAS)
[61], Sound Hypersensitivity Questionnaire [62], Hyperacu-
sis Questionnaire (HQ) [63], Hyperacusis test (12-item) [38],
a non-validated Hyperacusis Questionnaire adapted from
Gerau¨schu¨berempfindlichkeit (GU¨F [64]) [60], and Tinnitus
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“Decreased sound tolerance and difﬁculty 
adjusting to sudden shifts in volume 
which may not evoke any such reaction 
in a normal listener” [38].
“Reduced sound tolerance” [34].
“Lowered threshold for sound 
tolerance” [50].
“Decreased sound tolerance” [24].
“The collapse of loudness tolerance so 
that almost all sounds produce loudness 
discomfort even though the actual 
sound intensity is well below that 
judged to be uncomfortable by others” 
[43].
“A reduction of normal tolerance for 
everyday sounds” [60].
Reduction Reaction
“Noise intolerance to ordinary sounds, patients 
often present with emotional, social and physical 
symptoms” [58].
“A potentially disabling intolerance of moderate 
to loud sounds” [37].
“General intolerance to the loudness of sounds 
that would not typically be bothersome for most 
individuals” [30].
“Tolerance to loud sounds” [59].
“Intolerance to the loudness of sounds that most 
individuals deem to be tolerable” [21].
“Unusual tolerance to ordinary environmental 
sounds” or as “consistently exaggerated or 
inappropriate responses to sounds that are neither 
threatening nor uncomfortably loud to typical 
person” [19].
“Unusual intolerance to ordinary environmental 
sounds” [18].
“An unusual intolerance to ordinary environmental
 sounds” [41].
Intolerance
“Clinically significant, often highly distressing 
oversensitivity to common external sounds” [20].
“Auditory hypersensitivity” [46].
“Unusual hypersensitivity or discomfort induced by 
exposure to sound” [55].
Sensitivity
“Oversensitivity to sound” [35].
“Hypersensitivity to loud sounds” [29].
“An increased sensitivity to auditory stimulation” 
[53].
“Hypersensitivity and discomfort in the presence of 
common environmental noises (i.e. telephone, 
electric mixer) that would not trouble a normal 
person” [40].
Different from “normal”
Pt 1st
Pt SS
Pt SS
Pt 1st
Pt 1st
Pt 1st
Pt SS
Pt SS
Pt SS 
Pt 1st
Pt 1st
Pt 1st
“An abnormally strong response 
within the auditory pathways 
resulting from exposure to 
moderate sound” [22].
“An abnormally strong reaction to 
sound occurring within the auditory 
pathways” [36].
“An abnormal, generally painful 
perception of loudness in relation 
to all normal external noise” [23].
Pt 1st/2nd
Pt 1st
Pt SS
Pt 1st
Pt SS
Pt SS
Pt 2nd
Pt 2nd
Pt 2nd
Pt SS 
Pt SS
Pt 1st/SS 
Pt 1st
Pt/GPb 2nd
GPb 1st
Study population
Pt = patients recruited through 
clinics
GPb = general public
Complaint 
1st = hyperacusis primary 
complaint 
2nd = hyperacusis secondary 
complaint 
SS = hyperacusis within a 
symptom set 
Pt 1st
“A subject exhibits negative reactions 
following exposure to sound that 
would not evoke the same 
response in an average listener 
[. . . ] when negative reactions to a
sound depend only on its physical 
characteristics” [25].
“Bothersome loudness perception at moderate levels
[. . . ] referred to as auditory hypersensitivity” [39].
“Disproportionate growth in subjective loudness
of sounds. [. . . ] response on the part of an individual
“painful” to a patient experiencing hyperacusis. . . [49].
with normal hearing are judged “uncomfortable” or 
that sounds judged “soft” or “comfortable” to a listener 
“Abnormal sensitivity to sound, extreme sensitivity
and instability to some sounds within 3 dB of
thresholds” [42].
Figure 2: The four themes and underlying theme to emerge from the content of the working definitions of hyperacusis reported in the
included records.
Retraining Therapy (TRT) assessment interview [65]) were
reported to assess hyperacusis. Most commonly reported
were LDLs, the HQ and TRT assessment interview. The six
studies [18, 22, 24, 30, 31, 37] that reported using LDLs varied
in the dB values used to quantify hyperacusis. Gold et al. [22]
and Hazell et al. [24] specified that average LDLs should be
below 100 dB HL for 1, 2, 3, and 8 kHz in both ears (pure
tones), whilst Ju¨ris et al. [18] and Formby et al. [30] specified
that LDLs using pure tones should be ≤90 dB HL in at least
one ear at the frequencies of 0.5, 1, and 2 kHz or from at least
two frequencies in the range 0.5 kHz to 4 kHz, respectively.
In contrast, McKinney et al. [31] specified less commonly
used LDLs using pure tones of less than 88.39 dB SPL and
81.24 dB SPL to classify individuals as having hyperacusis
with normal hearing and hearing loss, respectively. Ruth and
Hamill-Ruth [37] did not specify any criteria for LDLs. A
similar case was found across the four studies reporting the
HQ [19, 45, 48, 58]. Only one study [19] specifically identified
a value on the HQ that would diagnose hyperacusis (36
points). Seven studies used the TRT assessment interview to
classify patients into one of five categories associated with
tinnitus and hyperacusis [24–27, 32–34]. Of these studies,
only Hazell et al. [24] explicitly referred to categories 3 and
4 (hyperacusis present).
The most commonly specified posttreatment outcome
measures were LDLs and the HQ (Tables 2–4). Nineteen
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studies reported increases in LDLs after treatment as either
a primary [18, 21–25, 30, 31, 33, 34, 42, 47, 60] or secondary
outcome [19, 28, 36, 38, 39, 58]. Six studies reported changes
in HQ scores as the primary outcome [19, 39, 45, 46, 48,
58] or secondary outcome measure [18]. Of the 43 included
records, 13 case studies [26, 35–37, 41, 43, 49, 50, 52–57] and
two cohort studies [29, 59] relied on patient self-reported
change in hyperacusis through clinical assessment at follow-
up. One study [20] did not state a hyperacusis-specific
outcomemeasure, only reporting the Tinnitus Questionnaire
[66] as an outcome measure. The remaining studies reported
a variety of different outcome measures, ranging from single
itemvisual analogue scales tomulti-itemhyperacusis-specific
questionnaires such as Multiple Activity Scale for Hyperacu-
sis (MASH) [67] and Sound Hypersensitivity Questionnaire
[62].
There is reasonable body of evidence on the development
and reliability of the HQ as a diagnostic tool [63, 68], but
the validity and reliability of the HQ as an outcome measure
are yet to be fully examined. Questions have been raised on
the appropriateness of the items in the questionnaire and the
need of validation in a population with a primary complaint
of hyperacusis is known [68]. Evidence for the reliability
of LDLs is variable [69, 70] with reliability depending on a
number of factors including instructions given to patients
[71] and choice of sound stimuli [8]. Importantly, there are
inconsistencies in the relationship between LDLs and self-
report sound tolerance, with LDLs (using pure tones or
speech sounds) often failing to reliably relate to self-reports
of tolerance sounds in daily life [72].
3.6. Current Management Options for Hyperacusis. All 43
included records reported potential treatment benefits for
hyperacusis (Tables 2–4). However, only nineteen studies
(44%) sought to evaluate interventions or management
strategies specifically aimed at reducing hyperacusis [18, 19,
21–25, 35, 38–43, 49, 56–58, 60]. For the most part, the
studies explored interventions that were primarily aimed
at reducing tinnitus. Management strategies explored were
Cognitive Behavioural Therapy (CBT), TRT, counselling,
devices, pharmacological therapy, and surgery.
3.7. Cognitive Behavioural Therapy. Three studies explored
the potential benefits of CBT [18–20] (Table 2). Ju¨ris et
al. [18] reported an RCT investigating the benefits of CBT
for patients experiencing hyperacusis. Treatment comprised
general CBT principles that were aimed to educate, target
overt emotional reactions to sounds though graded exposure
to sounds, reduce stress though relaxation, and provide
patients with the tools tomanagemore difficult situations and
restart activities (behavioural activation). After treatment,
patients in the CBT group showed a significant reduction in
hyperacusis severity as assessed by the HQ and an increase in
LDLs from baseline, compared to the waiting list group. Only
small effects were observed for quality of life and depression,
and symptoms of anxiety were unchanged. Fioretti et al. [19]
reported a case study in which a patient with hyperacusis
underwent a four-month course of pharmacological therapy
with bilateral sound generators (graded sound exposure) and
CBT to target fear of sounds. Reduced hyperacusis-related
symptoms were reported. Following this, the patient sus-
pended treatment and underwent chemotherapy for breast
cancer. Eight months later, after cancer treatment, the patient
reported worsening of hyperacusis symptoms. Serotonin
reuptake inhibitors and a further 4 months of CBT were
prescribed. Following treatment, the patient reported an
improvement in mood (depression, hostility, and sadness)
and sound tolerance. In this case, no details were provided on
the components of CBT. Hiller and Haerko¨tter [20] reported
an RCT investigating CBT and the possible additional effects
of sound stimulation on improving severity of tinnitus.
In this study, one group received treatment comprised of
an educational component (tinnitus education) in which
patients learned about and applied psychological concepts
such as “vicious cycle” and “coping cycle” to their personal
situations with tinnitus. The second group completed ten
sessions of CBT, including education (avoiding silence),
changing thought processes (relaxation), diverting atten-
tion, and identifying avoidant behaviours and short/long
terms consequences of behaviour. Half of each group were
supplied with sound stimulation through behind-the-ear
broadband white noise generators for each ear, with volume
controls for graded increases. Following treatment, greater
improvements in tinnitus severity were reported for patients
with hyperacusis compared to those without hyperacusis.
Notably, hyperacusis was notmeasured after treatment in this
study.
3.8. Tinnitus Retraining Therapy. Sixteen studies explored
the use of TRT for patients with hyperacusis as a primary
complaint [21–25] or a secondary complaint [26–33] or as
part of a symptom set [34–36] (Table 2.).
Nine studies [24–29, 32, 34, 35] focused on a classic
TRT protocol to elevate hyperacusis with/without tinnitus.
These studies incorporated a component of counselling
including educational training in which the Jastreboff neu-
rophysiological model is described to explain treatment
and demystify the patients’ experience. Guidance is given
about avoidance behaviour (e.g., use of earplugs, avoiding
environment sounds, or avoiding quiet) and the application
of desensitising sound and sound enrichment was discussed.
The depth of counselling and sound components depends
on the treatment category (0–4: presence of tinnitus, hearing
loss, hyperacusis, or noise exposure) assigned; for categories
1-2, sound generators are recommended; for categories 3-4
aimed at hyperacusis, bilateral open-fitting sound generators
are fitted with instructions to gradually increase the sound
daily to be tolerable without difficulties. Sound enrichment
techniques are also used, in which digitally produced nature
sounds are slowly reintroduced [24–29, 32, 34, 35]. Eight
of these studies reported improvements in hyperacusis [25,
27, 29, 32, 35], three of which reported increased LDLs
[24, 28, 34] following treatment. Hazell et al. [24] reported
that, after 2 years of treatment, LDLs were well within the
normal range (>100 dB) in over 60% of patients. In a case
series, Formby and Gold [34] found that individual patients
were reporting “noticeable subjective improvement in sound
tolerance,” resolution of complaints of discomfort, and in
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one case “complete resolve of sound tolerance problems.” In
a case report, Hesse et al. [35] described the need for the
patient to build up a good therapeutic relationship before
starting the sound exposure and generator component of
therapy. This led to hyperacusis only occurring on very rare
occasions. Both Suchova [29] and Molini et al. [27] reported
that only a small number of patients with hyperacusis showed
improvement following TRT. Molini et al. [27] reported
that only one patient in hyperacusis category 3 achieved
therapeutic success (a decrease of 2 or less on the scale of
symptoms, a Tinnitus Handicap Inventory Grade 1, and an
awareness of tinnitus value of less than or equal to 10%
of the patient’s wakefulness). In contrast, Forti et al. [26]
found that TRT led to patients reporting no differences in
difficulties with activities (relaxation, concentration, sleep,
social relations, and work) following the treatment.
Three studies evaluated the effectiveness of using sound
generators alongside directive counselling with patients
reporting a primary complaint of hyperacusis [21], tinnitus
[31], or hearing loss [30]. All three studies reported that LDLs
had significantly improved over the course of treatment. In
an RCT, Formby et al. [21] showed a clear pattern of LDLs
initially increasing and then plateauing at 6 months after the
onset of full treatment (counselling and noise generators).
All three studies also reported greater treatment success and
improvements of hyperacusis in patients who used noise
generators in addition to directive counselling than those
using part of the treatments (counselling alone, counselling
and placebo noise generator, or noise generator only). In
another RCT, Formby et al. [30] found that changes in
judgements of uncomfortable loudness for the full treatment
group after treatment averaged 15 dB–10 dB, compared to the
changes of 5 dB or less in the other groups.
Gold et al. [22] investigated functional auditory changes
demonstrated by increases in LDLs and DR during TRT for
patients with tinnitus and hyperacusis. Following treatment,
both LDLs and DR increased from the initial assessment
whilst hearing threshold did not change significantly. The
authors concluded that the DR can be increased following
TRT. Patients self-reported an increase in quality of life
and a decrease in the number of daily activities affected
by tolerance problems. Similarly, Wo¨lk and Seefeld [23]
reported that regular use of maskers (set at hearing threshold
and slowly increased) improved LDLs and DR and reduced
severity of hyperacusis to “no longer a problem.” Formby
and Keaser [33] explored the sound therapy component of
TRT and potential treatment benefits for tinnitus patients
using hearing aids (HA) versus audiometrically matched or
LDL-matched tinnitus patients with hyperacusis using noise
generators. Increases in LDLs and DR at follow-up were
observed for both the audiometrically matched and LDL-
matched groups. In the HA versus audiometrically matched
noise generator condition, changes in hearing thresholds
between groups were nominal, but patients using noise
generators showed significant increments in LDLs compared
to the HA group. In the HA versus LDL-matched noise
generator condition, the changes in LDLs at 1 kHz were
greater for the LDL-matched group than the HA group;
differences were negligible at other frequencies.
In a case study of a patient with posttraumatic stress
disorder reporting hyperacusis as a symptom, Westcott [36]
reported that, following an initial treatment of antidepres-
sants (a selective serotonin uptake inhibitor/a serotonin
and noradrenaline reuptake inhibitor) for sound intolerance
attributed to anxiety and depression, a TRT desensitisation
program was carried out to help increase tolerance to envi-
ronmental sounds. The patient self-reported an improved
ability to cope with loud sounds, reduced reaction to unex-
pected loud sounds, and the ability to actively pursue her own
piano playing.
One case report followed some of the TRT principles
without explicitly stating this method [37]. Ruth and Hamill-
Ruth [37] applied counselling with tinnitus habituation ther-
apy (bilateral fitted in-the-ear-noise generators) to improve
daily activities, relaxation, and mood monitoring in a patient
experiencing both tinnitus and hyperacusis. In addition to
therapy, the patient was prescribed Baclofen for pain and
sleep disturbance. After one year, the patient no longer expe-
rienced tinnitus or hyperacusis and reported an improved
ability to sleep and socialise.
3.9. Counselling Alone. Attri and Nagarkar [38] reported a
case study using hyperacusis-focused directive counselling to
educate the patient on the auditory system and mechanisms
of hyperacusis (Table 2). Guidance and advice were given
on avoiding silence, overprotection of ears, and use of
background sounds to desensitise hyperacusis. The patient
reported a reduction inHQ scores from 23 points (moderate)
to 15 points (close to normal) and improved tolerance
to sounds, with difficulties tending to occur only during
depressive episodes.
3.10. Devices Alone. Eleven studies reported the effects of
using different devices on patients with hyperacusis as a
primary complaint or secondary complaint or as part of
a symptom set (Table 3). Two studies [39, 40] reported
“acoustic training” for hyperacusis which notably improved
symptoms in the long term, with symptoms remaining in
remission over a year later. These studies slightly differed in
methodology.The seven “acoustic training” sessions (admin-
istered every 5 days) reported byMiani et al. [40] consisted of
six to ten stimulations in which a narrow band noise was sent
to an acoustic free field, before a 60 dB HL pure tone (other
types of sounds were also used in later sessions) was sent
through headphones for about 3 minutes followed by a pause
of 3minutes.The intensity of the sound stimulus andduration
were increased in 5 dB HL steps (up to a total increase of
35 dB HL) and up to 5 minutes of exposure, until the last
session, when the sound in the headphones reached 95 dB
HL in all frequencies. High frequencies used in the sessions
led to reports of discomfort by patients when listening via
headphones, but not in the acoustic free environment. These
sounds were not reflective of normal environmental sounds,
so authors were not concerned. In contrast, Noren˜a and
Chery-Croze [39] used passive exposure to an enriched
acoustic environment (EAE). Sounds used were pure tones
(based on the cut-off frequency of hearing loss) presented
in random order for the duration of 100ms with pauses
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between of 100ms. Participants listened to the EAE through
headphones for 1–3 hours a day at a just audible level.
Auditory sensitivity significantly decreased at all frequency
bands, from 2 weeks onwards. The impact of hyperacusis
on activities and daily functioning was reduced, with all
participants reporting significant decrease in both MASH
and HQ scores over the course of the treatment.
Three studies reported desensitisation programs using
broadband tinnitus maskers [41, 42] and pink noise tape
cassettes [43]. To desensitise patients, sounds were presented
in each ear through wearable tinnitus maskers or through
headphones (for pink noise) and started at a threshold the
patient could tolerate and gradually increased in loudness
over the sessions. In the case series reported by Vernon [41],
the patients wore ear plugs during the day and carried out the
desensitisation program at night. All three studies reported
improvements in hyperacusis, although somepatients did not
comply with the use of the tape cassettes as they were afraid
to use them because they believed that it would aggravate
their hyperacusis. One patient reported improved ability to
manage life without hyperacusis limitations [42].
One RCT [47] evaluated the effectiveness of a continuous
wave laser TinniTool versus a dummy laser device. A laser
probe was inserted into a specifically designed headset
which projects the laser beam (power output 5mW) onto
the tympanic membrane though a 17-degree diverging lens
(creating a spot size of 1 cm) for 20 minutes a day, resulting in
an energy density of around 6 J at themembrane.The placebo
dummy device, apart from activation of the laser beam,
reproduced all aspects of laser therapy. Tinnitus patients
in the laser therapy group reported decreased hyperacusis.
Seven patients in the laser therapy group and eight patients
in the placebo group reported LDLs lower than 80 dB at base-
line; of these, LDLs improved in five patients in laser therapy
group compared to two patients in placebo group following
treatment.
Two studies [44, 45] reported the long term effects of
cochlear implants (CI) treatment in patients with unilateral
hearing loss and tinnitus. Mertens et al. [45] found that
hyperacusis only significantly reduced for the single-sided
deafness group and not the asymmetric hearing loss group.
Significant differences were observed in HQ total and the
attentional subscale scores between the CI-ON and the CI-
OFF condition for the single-sided deafness group. Ramos
Mac´ıas et al. [44] reported that CI use resulted in improved
sound tolerance for six out of seven patients, who showed
a reduction in Sound Hypersensitivity Questionnaire scores
[62]. Only one patient showed decreased sound tolerance
problems. Saglier et al. [46] investigated the impact of family
history of hearing impairment on rehabilitation using HAs
and reported that hyperacusis scores were more improved in
patients without a family history following fitting ofHAs than
those with a family history.
One study [48] reported that 21 sessions using a tinnitus
progressive phase-shift treatment device (“Phase-outTM”),
which presented a sound that resembles the frequency and
amplitude of patients’ own tinnitus but shifts 6∘ every 30
seconds, did not significantly change scores on the HQ
or audiometric data between a pure tone tinnitus group
and a narrow band noise tinnitus group. All measurements
remained unchanged after therapy.
One case study [49] reported that diazide and methyl-
prednisolone improved unilateral hearing loss but did
not diminish hyperacusis. Following fitting of a custom-
made binaural full-concha, unvented in-the-ear compres-
sion device (Micro Tech Refuge-hyperacusic), the patient
reported that the devices were very helpful and provided
a level of protection that was at least as good as what
he achieved with the plugs and muffs, but reported that
he still could not carry out social activities (listening to
music, attending concerts, restaurants, movies, and events, or
hearing others when eating).
3.11. Pharmacological Therapy. Pharmacological therapy was
reported in five case studies [50–54] where hyperacusis was
part of a set of symptoms (Table 4). One case study [52]
reports a patient placed on a diet to address metabolic
factors, bisphosphonate and calcium, for otosclerosis. The
patient reported feeling better until the treatment regime was
discontinued, when symptoms of dizziness and hyperacusis
returned. The patient was prescribed bisphosphonate rise-
dronate and reported reduced complaints of symptoms and
feeling best when the diet regime was followed. In another
case study, Brookler [54] reported a patient prescribed met-
formin, risedronate (30mg twice weekly), calcium, vitamin
D, and sodium monofluorophosphate who reported wors-
ening of hyperacusis on days when they took risedronate.
Alternating the regime with etidronate (400mg/day for 2
weeks) and risedronate (30mg twice weekly for 4 weeks) did
not improve hyperacusis but increasing risedronate intake
to 30mg twice weekly for 6 weeks and then for 11 weeks
improved hyperacusis to be “almost gone.” Gopal et al. [51]
reported differences in LDLs between conditions inwhich the
patient was unmedicated and medicated with fluvoxamine
(50mg/day) and fluoxetine (20mg/day), with improved LDLs
above 100 dB in the medicated condition. Lee et al. [53]
reported that antihypertensives and gabapentin (600mg/day)
reduced the intensity of both tinnitus and hyperacusis after
1 month. Nields et al. [50] reported that although six weeks
of intravenous ceftriaxone led to a remission of “all symp-
toms,” excluding mild arthralgia and fatigue, hyperacusis
subsequently worsened after treatment. Intravenous cefo-
taxim slightly diminished hyperacusis, but it remained an
impediment to performing activities. Clonazepam led to a
short-term lessening of hyperacusis symptoms but increased
emotional lability. Following carbamazepine (blood level of
6 𝜇g/ml.), the patient reported that sound tolerance thresh-
olds had increased, fear and irritability had lessened, and the
kindling-like effects (sounds “adding up”) had diminished so
she was able to recover more quickly.
3.12. Surgery. Six studies reported results from patients
electing to undergo surgery specifically for hyperacusis
[56, 58, 60], hearing loss and hyperacusis [57], intracranial
aneurysms [55], or Meniere’s disease [59] (Table 4). In a
cohort study, J. Gavila´n and C. Gavila´n [59] performed a
middle fossa vestibular neurectomy, which includes ablation
of the vestibulofacial anastomosis, and removal of part of
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the nerve. They reported that hyperacusis symptoms had
lessened or were no longer a problem. Nikkar-Esfahani
et al. [56] reported that successful occlusion (permeatal
blocking) of the round window surgery in two patients led
to an improvement of conductive hyperacusis symptoms but
caused a mild exacerbation of conductive hearing loss. Khalil
et al. [55] reported a case study of a patient with hyperacusis
whose magnetic resonance imaging (MRI) revealed a large
aneurysm. A Guglielmi detachable coil (GDC) embolization
of the aneurysm led to resolution of hyperacusis. Dang et al.
[57] present a case of a patient with hearing loss and hyper-
acusis caused by bilateral superior semicircular canal dehis-
cence and posterior semicircular canal dehiscence. Surgery
involved a right-sided transmastoid approach and temporalis
fascia plugs of each defect. Hyperacusis was assessed as
resolved at three months’ follow-up. The patient did report
residual imbalance and right ear fullness, however. Two of the
most recent studies [58, 60] reported that transcranial round
window niche and oval window reinforcement surgery led
to improved hyperacusis, with increased LDLs and reduced
Hyperacusis Questionnaire scores (author-developed ques-
tionnaire adapted from the GU¨F [64]), but with no changes
to hearing. One patient reported sustained improvements of
hyperacusis and quality of life four years after surgery [58].
Silverstein et al. [60] reported higher success with unilateral
surgery than bilateral surgery.
3.13. Future Research Priorities Identified in the Literature.
Various further research priorities were identified in the
included records. Gabriels [42] urged audiologists to pool
their patient information together in order to study the link
between symptoms of hyperacusis combined with having a
limited DR. Most authors suggest that larger studies (Tables
2–4) need to be conducted to verify the effectiveness of CBT
[18], TRT [28, 32], and different surgical treatments [56, 58,
60]. Studies evaluating the treatment benefit of counselling
combined with alternative sound therapies (e.g., enriched
acoustic therapy [39]) compared to those usually used in TRT
should be conducted [30]. Larger studies focused on testing
the effect of maskers/noise generators and HAs specifically
for hyperacusis as a primary complaint are indicated [20, 21,
42]. Other possible treatments for hyperacusis suggested for
further research include laser therapy [47], desensitisation
techniques [41], and further investigation of the pharma-
ceutical treatments for certain subgroups of hyperacusis
specifically when hyperacusis is induced by Lyme disease [50]
or when cooccurring with depression [38]. Berry et al. [28]
also highlight the importance of developing patient-based
assessments for hyperacusis.
4. Discussion
This scoping review collated clinical research focused on
management strategies used for hyperacusis, the definitions
of hyperacusis, tools used for assessment and evaluation,
and future research priorities. We found that more than half
of the research currently reported was based on individual
case studies and therefore cannot be generalised. In addition
to this, management strategies were typically evaluated in
patients reporting hyperacusis as a secondary complaint or
as part of a symptom set, and as such the outcomes reported
only provided an indication of effectiveness for hyperacusis.
There is a lack of sufficient evidence to identify effective
management strategies. These findings highlight an urgent
need for controlled trials to evaluate the effectiveness of these
management strategies for patients experiencing hyperacusis.
The definitions characterised by researchers had com-
mon terminology, with descriptions mainly differing in the
emphasis placed on the direction of the sound tolerance,
either reduction in tolerance or oversensitivity. The under-
lying theme reflected how the sound tolerance in patients
with hyperacusis is different from “normal.” However, the
appropriateness of “hypersensitivity” as a term for problems
with sound tolerance has been questioned. Tyler et al. [12]
argued that hypersensitivity reflects hearing thresholds that
are better than normal and that hyperacusis is not usually
associated with this and as such recommended avoiding
using this terminology. The reference to “abnormal” could
be upsetting to patients and lead to negative reactions to
the experience. Although some studies referred to emotional
reactions, such as distress and discomfort, and physical
reactions of pain as characteristics of hyperacusis within their
working definitions, the four distinct definitions (loudness,
annoyance, fear, and pain) used in a recent narrative review
[12] of hyperacusis were not readily used in the literature.The
framework suggested by Tyler et al. [12] may be indicative
of characteristics of hyperacusis rather than defining discrete
subtypes that can be unambiguously differentiated. Conse-
quently, there is a need for consensus through a systematic
process involving professionals and patients to define hyper-
acusis and inform standards for assessment criteria.
To assess hyperacusis, most studies relied on self-report,
with only some studies reporting use of a tool (LDLs, the
HQ, or the TRT interview) to establish severity. Across the
board, no consistent diagnostic tools or criteria were used,
making it virtually impossible for comparisons across study
populations.There is a need for established diagnostic criteria
for hyperacusis and self-report measures appropriate for
the population which have been evaluated for this purpose.
The same can be said for outcome measures. The majority
of studies did not report the outcome measures used. For
case reports, the reliance was on clinical interview after
treatment, which can be meaningful as the findings directly
relate to patient experience. However, with the restricted
information reported, we can only have limited confidence
in the findings and the possible avenues for future research.
Otherwise, a variety of outcome measures were reported,
the most popular of which were LDLs and the HQ. Neither
has been fully evaluated as outcome measure and in terms
of the HQ was not designed to be used as an outcome
measure. The three response options only provide coarse-
grained categorical units of measurement and as such will
not reliably detect small but potentially meaningful changes
in hyperacusis [73, 74]. For LDLs, variability in the type of
sounds used and the instructions given to patients’ makes
comparisons across studies relatively meaningless. There is
an apparent need for clear guidance and consensus on
LDLs use as outcome measures and for the development of
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self-report questionnaire specifically aimed at being respon-
sive to changes in the impact of hyperacusis.
The most commonly reported management strategy was
TRT, and most studies indicated that the treatment was
beneficial to patients with hyperacusis. Complex interven-
tions that include several interacting components require
systematic evaluations [14]. Most included records reported
here lacked rigorous methodology, raising concerns about
the validity of the findings. Having said this, the RCTs
using patients with a primary complaint [21] or secondary
complaint of hyperacusis [30] did provide empirical evidence
for the combination of the counselling and sound therapy
components (full treatment) being of more benefit than the
single components and as such highlighting an important
principle of TRT. For the most part, there was a lack of rigor
in reporting what was done in the name of TRT, particularly
details of the counselling components used throughout the
sessions or any differences when treating tinnitus and hyper-
acusis.
Despite the earliest research reported being published
in the 1980s, there is an absence of research evidence
on treatments directly aimed at treating hyperacusis. Most
studies reported here were not focused on hyperacusis as
the primary reason for management.This was especially true
for the pharmacological treatments, all of which reported
hyperacusis as part of a set of symptoms and were case
studies; the effects observed may not be representative of
the general hyperacusis population.The drugs reported were
in general aimed at alleviating other symptoms and the
reduction of hyperacusis may have been a byproduct of
the reduction in those symptoms. Without the appropriate
population, sample size, and systematic trialmethodology, no
strong conclusions can be reached.
Overall, only five of the 43 studies used a RCT design
[18, 20, 21, 30, 47], two of which were solely aimed at
patients experiencing hyperacusis [18, 21]. Whilst there are
challenges in utilising a placebo control in interventions
that involve sound therapy and/or counselling, waiting list
controls designs could be implemented, as could a standard
care versus specialist care design. The use of more robust
trial designs in future hyperacusis studies would increase
the quality and value of the evidence and support the
development of optimised treatments.
5. Conclusions
Clear themes were identified from the definitions of hyper-
acusis reported, with an underlying theme that highlights
the difference in sound tolerance from what is considered
“normal.” In order to enable diagnosis and assessment, there
needs to be an agreement on the definition including the
perspectives of patients with lived experience of hyperacusis.
The majority of management strategies were evaluated in
patients reporting hyperacusis as a secondary complaint or as
part of a symptom set and as such the outcomes only highlight
potential benefits and no strong conclusions can be made.
Authors agree that research should prioritise evaluating
interventions and management strategies on patients with
hyperacusis as a primary complaint, in particular TRT, sound
therapy interventions, and pharmacological interventions.
Importantly, to establish the benefits within this population,
there is a need for controlled trials and appropriate patient-
based assessments specifically for measuring hyperacusis. To
date, only two controlled trials primarily aimed at hyperacu-
sis have been conducted and as yet there are no registered
ongoing or planned trials for hyperacusis as a primary
complaint. With such an open field, it is essential that these
opportunities for new research highlighted here lead to new
controlled trials that will have a greater impact on the field.
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